+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

DAIICHI SANKYO - Edoxaban Gets Edge as Key Japanese Factor-Xa Inhibitors Fall!

1 of 4
Recent failures of Edoxaban’s key competitor factor-Xa inhibitors from Japan - YM 150 (Astellas) and TAK-442 (Takeda), the closest candidate in Japan now is Xarelto (Bayer), which is still ~1 years away from hitting the market. Edoxaban is the first and only approved factor-Xa inhibitor in Japan for prevention of VTE, though Japanese VTE opportunity is not big but it will enhance investors’ confidence regarding its global success where the opportunity is huge. Edoxaban is behind Xarelto in development for AF (~2 years). However, considering its high market potential it remains attractive as it is the only drug that has shown dose response in this class
Note: Product cover images may vary from those shown
2 of 4

Loading
LOADING...

3 of 4
- Edoxaban
- YM150
- TAK-442
- Factor Xa candidates
- Xarelto
- Apixaban
- ICT data
- VTE
- AF
- Factor Xa pipeline
- Anticoagulants market
- Betrixaban
- Astellas
- Takeda
- Bayer
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll